Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Trial Title: Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

NCT ID: NCT05481463

Condition: Pancreatic Neoplasms

Conditions: Official terms:
Pancreatic Neoplasms

Study type: Interventional

Study phase: Phase 2

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Surufatinib
Description: surufatinib,250mg, qd, po, 28 days for a cycle
Arm group label: surufatinib combined with TAS-102

Intervention type: Drug
Intervention name: TAS-102
Description: TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle
Arm group label: surufatinib combined with TAS-102

Summary: This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer

Detailed description: surufatinib:250mg,QD,Q4W TAS-102:35mg/m2,D1-5,D8-12,Q4W

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Informed consent has been signed 2. Histologically or cytologically confirmed unresectable, locally advanced or metastatic pancreatic cancer 3. Age ≥ 18 years, ≤75 years, male or female 4. ECOG PS：0-1, expected overall survival ≥12 months 5. Patients who have previously received at least two systemic therapies for locally advanced or metastatic pancreatic cancer; patients with BRCA1/2 germline mutations have previously received platinum-containing regimens 6. Patients must have at least one measurable liver metastases (RECIST 1.1) 7. No serious organic diseases of the heart, lungs, brain and other organs 8. Patients must have adequate organ and bone marrow function 9. Women of childbearing age must have a negative pregnancy test within the first day of the study, and contraceptive methods should be taken during the study until 6 months after the last administration Exclusion Criteria: 1. Participated in clinical trials of other anti-tumor drugs within 4 weeks before enrollment 2. Previously received VEGFR inhibitors or immune checkpoint inhibitors 3. Patients had other malignant tumors in the past 5 years, except for the cured skin basal cell carcinoma and cervical carcinoma in situ 4. Patients previously had brain metastasis or current brain metastasis 5. Received any operation (except biopsy) or invasive treatment or operation (except venous catheterization, puncture and drainage, internal/external drainage surgery for obstructive jaundice, etc.) within 4 weeks before enrollment 6. Clinically significant electrolyte abnormality 7. Patient currently has uncontrolled hypertension, defined as: systolic blood pressure > 140mmHg or diastolic blood pressure > 90mmHg 8. Proteinuria ≥ 2+ (1.0g/24hr) 9. Patients whose tumor is highly likely to invade important blood vessels and cause fatal hemorrhage during the follow-up study as judged by the investigator 10. Have evidence or history of bleeding tendency within 3 months, significant bleeding symptoms or a clear bleeding tendency within 3 months before enrollment 11. Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris or coronary artery bypass grafting within 6 months before enrollment; NYHA classification > 2 Grade; ventricular arrhythmia requiring medical therapy; ECG showing QTc interval ≥ 480 ms 12. Active or uncontrolled serious infection (≥CTCAE grade 2 infection) 13. Unrelieved toxic reactions ≥ CTCAE grade 2 due to any previous anticancer treatment, excluding alopecia, lymphopenia and neurotoxicity of ≤ grade 2 caused by oxaliplatin 14. Pregnant or lactating women 15. Any other disease, with clinically significant metabolic abnormalities, physical examination abnormalities or laboratory abnormalities, according to the judgment of investigator that the patient is not suitable for the the study drug (such as having epileptic seizures and require treatment), or would affect the interpretation of study results, or put patients at high risk 16. Clinical confirmed human immunodeficiency virus (HIV) infection, history of clinically significant liver disease, including viral hepatitis (hepatitis B / C (HBV DNA Positive[1×104 copies/mL or >2000 IU/ml], HCV RNA positive[>1×103 copies/mL]), or other hepatitis, cirrhosis]) 17. Patients with autoimmune disease or suspected autoimmune disease (including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, enteritis, multiple Sclerosis, vasculitis, glomerulonephritis, uveitis, hypophysitis, hyperthyroidism, etc.) 18. Patients who are allergic or suspected to be allergic to the study drug or similar drugs 19. Patients have other factors that may affect the results of the study or cause the study to be terminated halfway, such as alcoholism, drug abuse, other serious diseases (including mental diseases) that require concomitant treatment, and serious laboratory abnormalities. Accompanied by family or social factors, which will affect the safety of patients

Gender: All

Minimum age: 18 Years

Maximum age: 75 Years

Healthy volunteers: No

Locations:

Facility:
Name: Cancer center of SunYat-sen University

Address:
City: Guangzhou
Zip: 510060
Country: China

Status: Recruiting

Contact:
Last name: Dongsheng Zhang, MD,PhD

Phone: 86-2087343795
Email: zhangdsh@sysucc.org.cn

Start date: March 28, 2022

Completion date: August 2025

Lead sponsor:
Agency: Sun Yat-sen University
Agency class: Other

Source: Sun Yat-sen University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05481463